Last edition
News about "Lonza"
Octane Medical Group to Acquire Personalised Medicine Unit from Lonza
Octane Medical Group has signed an agreement to acquire the personalised medicine business of Lonza, including the Cocoon cell-therapy platform. The deal aims to expand Octane’s capabilities in advanced therapies and strengthen its presence in the rapidly growing personalised medicine sector.
Lonza | 06/03/2026 | By News Bureau | 121
Lonza has received Swissmedic approval for its new state-of-the-art aseptic filling line in Stein (CH), designed for biologics and highly potent products, including antibody-drug conjugates (ADCs).
Lonza | 10/10/2025 | By Dineshwori | 207
Lonza Expands TheraPEAK Product Portfolio, Launches AmpliCell Cytokines and TheraPEAK 293-GT Medium
Switzerland-based Lonza has expanded its GMP solutions for cell and gene therapy with the launch of TheraPEAK AmpliCell Cytokines and TheraPEAK 293-GT Medium.
Lonza | 07/10/2025 | By Dineshwori | 251
Exogenus Picks Lonza to Develop GMP-Compliant Process to Manufacture Exo-101
Exogenus Therapeutics specializes in the development of healthcare solutions based on extracellular vesicles, including exosomes and other nanotechnologies.
Lonza | 12/03/2025 | By Aishwarya | 421
Iconovo and Lonza to Develop Formulation of Intranasal Biologic
This project, with a reformulated substance for obesity, is the first in Iconovo’s strategic initiative to reformulate known pharmaceuticals and replace injections and oral treatments with inhalation.
Lonza | 14/01/2025 | By Aishwarya | 340
Lonza Completes its First GMP Batch of Next-Gen Mammalian Manufacturing Facility in US
The first GMP batch release marks a significant milestone, allowing the facility to help meet the increasing market demand for small- to mid-scale volumes of mammalian-derived biologics and support the implementation of high-titer and high-throughput platform processes.
Lonza | 25/11/2024 | By Aishwarya | 525
Acumen Pharma Extends Partnership with Lonza to Support Manufacturing of Sabirnetug
Sabirnetug is the first humanized monoclonal antibody to clinically demonstrate selective target engagement of AβOs in AD patients.
Lonza | 30/09/2024 | By Aishwarya | 360
Lonza Inaugurates Innovaform Accelerator CoE in France
The new Innovaform Accelerator will serve as a Center of Excellence (CoE) for developing and innovating capsule-based manufacturing and delivery solutions for oral and pulmonary administration.
Lonza | 20/09/2024 | By Aishwarya | 392
Champalimaud Foundation to Leverage Lonza Platform to Advance Cell Therapy
Champalimaud Foundation, a biomedical clinical research organization carrying out research and cutting-edge clinical development and discoveries that benefit people, and Lonza have announced the installation of Lonza’s MODA-ES Platform at the Champalimaud Clinical Centre in Lisbon, Portugal.
Lonza | 13/08/2024 | By Aishwarya | 786
TriLink Signs Non-Exclusive License and Supply Agreement with Lonza
TriLink BioTechnologies has signed a non-exclusive License and Supply Agreement with Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries.
Lonza | 02/05/2024 | By Aishwarya | 665
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy